Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arcturus Therapeutics Holdings Inc. (ARCT)
USD6.38
+0.01 (+0.16%)
US NASDAQ Healthcare Biotechnology
Address
10628 Science Center Drive 92121
San Diego, CA, US
San Diego, CA, US
CEO
Joseph E. Payne
Website
arcturusrx.com
IPO
2013-05-22
CIK 1768224 ISIN US03969T1097
Description
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| NASDAQ | ADHD | 2019-03-15 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.38
+0.01 (+0.16%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
433.2K
Beta
2.36
Float Shares
26.28M
Free Float %
92.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.46% | +0.36% | -2.48% | +14.42% | +6.18% | +34.58% | -30.44% | -73.07% | -68.01% | -70.76% | -84.39% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (21 ratings, all time)
Buy
Price Targets & DCF
Current price
6.38
Low
20.00
+213.5%
Consensus
22.50
+252.7%
Median
22.50
+252.7%
High
25.00
+291.8%
Ratings Trend (MoM)
77% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 8 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
25.00
+291.8%
|
| Last Year | 4 |
32.75
+413.3%
|
| All Time | 14 |
22.93
+259.4%
|
Quality scores
Altman Z-Score
-0.31
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-51.4% Q1'26: -97.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+20.0% Q1'26: -82.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-165.7% Q1'26: -3,187.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-111.5% Q1'26: -4,882.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-928.4% Q1'26: +35,771.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.4% ★ Q1'26: +4.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.35× Q1'26: -0.17× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 8 EPS Ana. |
Dec 2027 8 Rev. Ana. 9 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
15.75M
est: 11.47M (+37.4%)
|
20.79M
est: 21.45M (-3.1%)
|
9.54M
est: 9.76M (-2.2%)
|
12.36M
est: 23.84M (-48.2%)
|
205.76M
est: 53.87M (+281.9%)
|
157.75M
est: 124.53M (+26.7%)
|
138.39M
est: 169.49M (-18.4%)
|
67.22M
est: 90.77M (-25.9%)
|
16.99M
7.98M – 26.60M
-81.3% YoY
|
41.23M
11.14M – 125.99M
+142.6% YoY
|
121.78M
115.24M – 128.31M
+195.4% YoY
|
275.91M
125.91M – 1.15B
+126.6% YoY
|
431.11M
196.74M – 1.79B
+56.2% YoY
|
| EBITDA |
-20.72M
est: -6.07M (-241.3%)
|
-24.45M
est: -11.35M (-115.5%)
|
-70.64M
est: -5.16M (-1,268.3%)
|
-201.66M
est: -163.99M (-23.0%)
|
13.70M
est: -188.69M (+107.3%)
|
-24.17M
est: -65.90M (+63.3%)
|
-77.40M
est: -89.69M (+13.7%)
|
-71.93M
est: -48.03M (-49.8%)
|
-8.99M
-14.07M – -4.22M
+81.3% YoY
|
-21.82M
-66.67M – -5.90M
-142.6% YoY
|
-64.44M
-67.90M – -60.98M
-195.4% YoY
|
-146.01M
-606.49M – -66.63M
-126.6% YoY
|
-228.13M
-947.64M – -104.11M
-56.2% YoY
|
| EBIT |
-21.30M
est: -6.19M (-244.2%)
|
-25.14M
est: -11.57M (-117.2%)
|
-71.52M
est: -5.26M (-1,258.7%)
|
-202.85M
est: -165.05M (-22.9%)
|
12.18M
est: -188.42M (+106.5%)
|
-27.12M
est: -67.19M (+59.6%)
|
-80.95M
est: -91.45M (+11.5%)
|
-74.96M
est: -48.97M (-53.1%)
|
-9.17M
-14.35M – -4.30M
+81.3% YoY
|
-22.25M
-67.97M – -6.01M
-142.6% YoY
|
-65.70M
-69.23M – -62.17M
-195.4% YoY
|
-148.86M
-618.36M – -67.94M
-126.6% YoY
|
-232.60M
-966.18M – -106.15M
-56.2% YoY
|
| Net Income |
-21.79M
est: -68.47M (+68.2%)
|
-25.99M
est: -49.14M (+47.1%)
|
-72.15M
est: -81.43M (+11.4%)
|
-203.67M
est: -166.49M (-22.3%)
|
9.35M
est: -191.63M (+104.9%)
|
-29.73M
est: -107.30M (+72.3%)
|
-80.94M
est: -68.20M (-18.7%)
|
-65.78M
est: -54.76M (-20.1%)
|
-121.37M
-144.60M – -80.71M
-121.6% YoY
|
-124.50M
-146.75M – 11.01M
-2.6% YoY
|
-36.93M
-234.99M – 660.29M
+70.3% YoY
|
47.72M
13.99M – 243.38M
+229.2% YoY
|
157.61M
46.22M – 803.80M
+230.3% YoY
|
| SGA |
20.58M
est: 15.89M (+29.5%)
|
12.66M
est: 29.72M (-57.4%)
|
25.12M
est: 13.52M (+85.8%)
|
41.45M
est: 33.04M (+25.5%)
|
46.07M
est: 42.07M (+9.5%)
|
52.87M
est: 124.03M (-57.4%)
|
52.82M
est: 168.82M (-68.7%)
|
46.08M
est: 90.41M (-49.0%)
|
16.93M
7.95M – 26.49M
-81.3% YoY
|
41.07M
11.10M – 125.49M
+142.6% YoY
|
121.29M
114.78M – 127.81M
+195.4% YoY
|
274.82M
125.42M – 1.14B
+126.6% YoY
|
429.40M
195.96M – 1.78B
+56.2% YoY
|
| EPS |
-2.16
est: -2.54 (+14.8%)
|
-2.13
est: -1.82 (-17.0%)
|
-3.55
est: -3.02 (-17.7%)
|
-7.74
est: -7.87 (+1.6%)
|
0.35
est: -5.83 (+106.0%)
|
-1.12
est: -4.02 (+72.1%)
|
-3.00
est: -2.43 (-23.3%)
|
-2.40
est: -2.06 (-16.3%)
|
-4.01
-5.28 – -2.95
-94.5% YoY
|
-3.74
-5.36 – 0.40
+6.8% YoY
|
-1.65
-8.58 – 24.11
+55.8% YoY
|
1.74
0.51 – 8.89
+205.4% YoY
|
5.76
1.69 – 29.35
+230.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-84.49M
OE per share TTM
-3.06
Owner's Yield
-33.40%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
29.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
25
Total invested
19.77M
Insider transactions (90d)
1
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Federated Hermes, Inc. | 3.69M | 14.02% | 3.69M | — | 3.69M | — | HC | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 2 | J. Christopher Donahue | 3.69M | 14.02% | — | 3.69M | — | 3.69M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 3 | Rhodora J. Donahue | 3.69M | 14.02% | — | 3.69M | — | 3.69M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 4 | Thomas R. Donahue | 3.69M | 14.02% | — | 3.69M | — | 3.69M | IN | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 5 | Voting Shares Irrevocable Trust | 3.69M | 14.02% | 3.69M | — | 3.69M | — | OO | Citizenship or place of Organization | 2022-02-14 | ↗ |
| 6 | STATE STREET CORPORATION | 3.22M | 12.20% | — | 3.17M | — | 3.22M | HC | BOSTON, MASSACHUSETTS | 2022-04-11 | ↗ |
| 7 | ARK Investment Management LLC | 2.85M | 10.84% | 2.85M | — | 2.85M | — | IA | Delaware, United States | 2021-11-09 | ↗ |
| 8 | SSGA FUNDS MANAGEMENT, INC. | 2.78M | 10.52% | — | 2.77M | — | 2.78M | IA | BOSTON, MASSACHUSETTS | 2022-04-11 | ↗ |
| 9 | Nikko Asset Management Americas, Inc. | 2.32M | 8.56% | — | 2.04M | — | 2.32M | IA | USA | 2024-11-08 | ↗ |
| 10 | Nikko Asset Management Co., Ltd. (“NAM”) | 2.32M | 8.56% | — | 2.32M | — | — | FI, IA, HC | Japan | 2024-11-05 | ↗ |
| 11 | Sumitomo Mitsui Trust Group, Inc. (“SMTG”) | 2.32M | 8.56% | — | 2.32M | — | — | FI, HC | Japan | 2024-11-05 | ↗ |
| 12 | (1) BlackRock, Inc. | 1.76M | 6.70% | 1.72M | — | 1.76M | — | HC | Delaware | 2022-02-03 | ↗ |
| 13 | The Vanguard Group - 23-1945930 | 1.45M | 5.46% | — | — | 1.39M | 56.2K | IA | Pennsylvania | 2023-02-09 | ↗ |
| 14 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | 1.36M | 5.14% | — | 1.36M | — | 1.36M | FI, HC | Japan | 2022-02-04 | ↗ |
| 15 | 27-2546083 | 1.20M | 4.60% | 1.20M | — | 1.20M | — | CO | — | 2021-10-26 | ↗ |
| 16 | Arcturus Therapeutics Holdings Inc. | 843.8K | 12.38% | 843.8K | — | 843.8K | — | CO | United States | 2022-02-15 | ↗ |
| 17 | 52-0556948 | 15.0K | 0.00% | 3.8K | — | — | — | IA | Maryland | 2022-02-14 | ↗ |
| 18 | Arthur Cohen | — | 0.00% | — | — | — | — | IN | United States | 2021-02-12 | ↗ |
| 19 | Bihua Chen | — | 0.00% | — | — | — | — | IN | Cayman Islands | 2021-02-16 | ↗ |
| 20 | Cormorant Asset Management, LP | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2021-02-16 | ↗ |
| 21 | Cormorant Global Healthcare GP, LLC | — | 0.00% | — | — | — | — | OO | Cayman Islands | 2021-02-16 | ↗ |
| 22 | Cormorant Global Healthcare Master Fund, LP | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2021-02-16 | ↗ |
| 23 | HealthCor Associates, LLC | — | 0.00% | — | — | — | — | OO | CITIZENship or place of organization | 2021-02-12 | ↗ |
| 24 | HealthCor Group, LLC | — | 0.00% | — | — | — | — | OO | CITIZENship or place of organization | 2021-02-12 | ↗ |
| 25 | HealthCor Management, L.P. | — | 0.00% | — | — | — | — | PN | CITIZENship or place of organization | 2021-02-12 | ↗ |
| 26 | HealthCor Offshore GP, LLC | — | 0.00% | — | — | — | — | OO | CITIZENship or place of organization | 2021-02-12 | ↗ |
| 27 | HealthCor Offshore II GP, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2021-02-12 | ↗ |
| 28 | HealthCor Offshore Master Fund, L.P. | — | 0.00% | — | — | — | — | PN | CITIZENship or place of organization | 2021-02-12 | ↗ |
| 29 | HealthCor Sanatate Offshore Master Fund, L.P. | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2021-02-12 | ↗ |
| 30 | HealthCor Therapeutics GP, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2021-02-12 | ↗ |
| 31 | HealthCor Therapeutics Master Fund, L.P. | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2021-02-12 | ↗ |
| 32 | Joseph Healey | — | 0.00% | — | — | — | — | IN | United States | 2021-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
25
-106 vs prev Q
New positions
5
Closed positions
102
Increased
17
Reduced
4
Put/Call ratio
0.00
Calls held
1.3K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NVERSES CAPITAL, LLC | 22.9K +22.9K (+100.0%) | 140.40M +140.4M (+100.0%) | 0.08% +0.084 pp | 0.31% +0.315 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 2 | FEDERATED HERMES, INC. | 3.30M -1.4M (-29.6%) | 20.25M -66.3M (-76.6%) | 12.15% -5.152 pp | 0.03% -0.119 pp | USD36.71 -83.3% | 23 qtrs — |
| 3 | BLACKROCK, INC. | 2.62M +55.0K (+2.1%) | 16.06M -31.2M (-66.0%) | 9.64% +0.182 pp | 0.00% -0.001 pp | USD22.77 -73.1% | 6 qtrs — |
| 4 | ARK INVESTMENT MANAGEMENT LLC | 2.61M +738.4K (+39.4%) | 16.01M -18.5M (-53.6%) | 9.60% +2.701 pp | 0.11% -0.099 pp | USD21.57 -71.6% | 27 qtrs — |
| 5 | VANGUARD GROUP INC | 2.09M +204.0K (+10.8%) | 12.81M -21.9M (-63.1%) | 7.69% +0.735 pp | 0.00% 0.000 pp | USD28.19 -78.3% | 26 qtrs — |
| 6 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 2.03M +78.8K (+4.0%) | 12.42M -23.5M (-65.4%) | 7.45% +0.274 pp | 0.01% -0.013 pp | USD27.33 -77.6% | 27 qtrs — |
| 7 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 2.03M +78.8K (+4.0%) | 12.40M -23.5M (-65.4%) | 7.45% +0.274 pp | 0.14% -0.204 pp | USD27.33 -77.6% | 27 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 618.1K +6.3K (+1.0%) | 3.79M -7.5M (-66.4%) | 2.27% +0.018 pp | 0.00% -0.001 pp | USD29.86 -79.5% | 27 qtrs — |
| 9 | STATE STREET CORP | 564.3K -481.4K (-46.0%) | 3.46M -15.8M (-82.1%) | 2.08% -1.779 pp | 0.00% -0.001 pp | USD34.47 -82.2% | 23 qtrs — |
| 10 | TWO SIGMA INVESTMENTS, LP | 546.7K +457.5K (+512.7%) | 3.35M +1.7M (+103.8%) | 2.01% +1.682 pp | 0.00% +0.002 pp | USD7.73 -20.7% | 12 qtrs — |
| 11 | TWO SIGMA ADVISERS, LP | 511.0K +472.5K (+1,227.4%) | 3.13M +2.4M (+341.5%) | 1.88% +1.738 pp | 0.01% +0.005 pp | USD6.65 -7.8% | 3 qtrs — |
| 12 | DIMENSIONAL FUND ADVISORS LP | 490.4K -65.0K (-11.7%) | 3.01M -7.2M (-70.6%) | 1.80% -0.244 pp | 0.00% -0.002 pp | USD25.99 -76.4% | 17 qtrs — |
| 13 | ACADIAN ASSET MANAGEMENT LLC | 427.9K +191.5K (+81.0%) | 2.62M -1.7M (-39.8%) | 1.57% +0.703 pp | 0.00% -0.003 pp | USD10.80 -43.2% | 6 qtrs — |
| 14 | EMPIRE LIFE INVESTMENTS INC. | 412.4K -5.2K (-1.2%) | 2.53M -5.2M (-67.2%) | 1.52% -0.022 pp | 0.14% -0.308 pp | USD19.63 -68.8% | 6 qtrs — |
| 15 | GOLDMAN SACHS GROUP INC | 391.2K +246.5K (+170.3%) | 2.40M -269.1K (-10.1%) | 1.44% +0.906 pp | 0.00% +0.000 pp | USD13.32 -54.0% | 25 qtrs — |
| 16 | MILLENNIUM MANAGEMENT LLC | 304.8K +265.0K (+665.8%) | 1.87M +1.1M (+154.7%) | 1.12% +0.974 pp | 0.00% +0.001 pp | USD7.74 -20.8% | 15 qtrs — |
| 17 | JACOBS LEVY EQUITY MANAGEMENT, INC | 293.1K -12.6K (-4.1%) | 1.80M -3.8M (-68.1%) | 1.08% -0.049 pp | 0.01% -0.015 pp | USD16.81 -63.5% | 11 qtrs — |
| 18 | HENNION & WALSH ASSET MANAGEMENT, INC. | 240.3K +161.9K (+206.5%) | 1.47M +28.3K (+2.0%) | 0.88% +0.595 pp | 0.05% -0.002 pp | USD10.93 -43.9% | 19 qtrs — |
| 19 | UBS GROUP AG | 227.9K +67.4K (+42.0%) | 1.40M -1.6M (-52.8%) | 0.84% +0.247 pp | 0.00% 0.000 pp | USD16.88 -63.7% | 27 qtrs — |
| 20 | POINT72 ASSET MANAGEMENT, L.P. | 222.2K +222.2K (+100.0%) | 1.36M +1.4M (+100.0%) | 0.82% +0.817 pp | 0.00% +0.002 pp | USD6.13 +0.0% | 4 qtrs — |
| 21 | MORGAN STANLEY | 213.4K -491.5K (-69.7%) | 1.31M -11.7M (-89.9%) | 0.78% -1.813 pp | 0.00% -0.001 pp | USD21.07 -70.9% | 27 qtrs — |
| 22 | JPMORGAN CHASE & CO | 206.2K +2.6K (+1.3%) | 1.26M -2.5M (-66.3%) | 0.76% +0.008 pp | 0.00% 0.000 pp | USD36.56 -83.2% | 27 qtrs — |
| 23 | DEKABANK DEUTSCHE GIROZENTRALE | 43.9K +— (+0.0%) | 1.24M +12.0K (+1.0%) | 0.16% 0.000 pp | 0.00% +0.000 pp | USD28.58 -78.6% | 11 qtrs — |
| 24 | NORTHERN TRUST CORP | 200.8K -17.1K (-7.8%) | 1.23M -2.8M (-69.3%) | 0.74% -0.065 pp | 0.00% 0.000 pp | USD35.67 -82.8% | 26 qtrs — |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 183.9K -25.6K (-12.2%) | 1.13M -2.7M (-70.8%) | 0.68% -0.096 pp | 0.00% 0.000 pp | USD35.42 -82.7% | 23 qtrs — |
| 26 | BNP PARIBAS ARBITRAGE, SNC | 146.8K +139.9K (+2,043.2%) | 899.7K +773.5K (+612.9%) | 0.54% +0.515 pp | 0.00% +0.000 pp | USD6.65 -7.8% | 23 qtrs — |
| 27 | RENAISSANCE TECHNOLOGIES LLC | 119.9K +119.9K (+100.0%) | 735.0K +735.0K (+100.0%) | 0.44% +0.441 pp | 0.00% +0.001 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 28 | ATOM INVESTORS LP | 106.4K +106.4K (+100.0%) | 652.2K +652.2K (+100.0%) | 0.39% +0.391 pp | 0.05% +0.052 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 29 | JANE STREET GROUP, LLC | 106.3K +82.4K (+344.8%) | 651.6K +211.1K (+47.9%) | 0.39% +0.303 pp | 0.00% +0.000 pp | USD7.68 -20.2% | 6 qtrs — |
| 30 | INVESCO LTD. | 103.1K +38.6K (+59.9%) | 632.1K -556.4K (-46.8%) | 0.38% +0.142 pp | 0.00% 0.000 pp | USD13.88 -55.8% | 23 qtrs — |
| 31 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 103.1K +7.2K (+7.5%) | 631.9K -1.1M (-64.3%) | 0.38% +0.026 pp | 0.01% -0.018 pp | USD13.31 -53.9% | 3 qtrs — |
| 32 | D. E. SHAW & CO., INC. | 97.8K +37.6K (+62.5%) | 599.7K -510.1K (-46.0%) | 0.36% +0.138 pp | 0.00% 0.000 pp | USD13.12 -53.3% | 3 qtrs — |
| 33 | IQ EQ FUND MANAGEMENT (IRELAND) LTD | 91.6K +47.6K (+108.2%) | 561.4K -249.1K (-30.7%) | 0.34% +0.175 pp | 0.04% -0.016 pp | USD10.13 -39.5% | 4 qtrs — |
| 34 | CITADEL ADVISORS LLC | 86.2K +35.3K (+69.4%) | 528.4K -409.7K (-43.7%) | 0.32% +0.129 pp | 0.00% 0.000 pp | USD13.56 -54.8% | 23 qtrs — |
| 35 | XTX TOPCO LTD | 82.2K +82.2K (+100.0%) | 503.6K +503.6K (+100.0%) | 0.30% +0.302 pp | 0.01% +0.013 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 36 | BANK OF NEW YORK MELLON CORP | 76.3K -12.4K (-13.9%) | 467.7K -1.2M (-71.4%) | 0.28% -0.046 pp | 0.00% 0.000 pp | USD33.38 -81.6% | 23 qtrs — |
| 37 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 74.7K -459.3K (-86.0%) | 458.1K -9.4M (-95.3%) | 0.27% -1.694 pp | 0.00% -0.001 pp | USD18.29 -66.5% | 27 qtrs — |
| 38 | SCHONFELD STRATEGIC ADVISORS LLC | 69.8K -598.1K (-89.6%) | 427.6K -11.9M (-96.5%) | 0.26% -2.205 pp | 0.00% -0.068 pp | USD21.93 -72.0% | 10 qtrs — |
| 39 | ENGINEERS GATE MANAGER LP | 68.2K +68.2K (+100.0%) | 417.9K +417.9K (+100.0%) | 0.25% +0.251 pp | 0.01% +0.005 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 40 | WOODLINE PARTNERS LP | 66.6K +— (+0.0%) | 408.1K -818.9K (-66.7%) | 0.24% -0.001 pp | 0.00% -0.004 pp | USD18.73 -67.3% | 14 qtrs — |
| 41 | AMERICAN CENTURY COMPANIES INC | 66.5K +2.0K (+3.2%) | 407.6K -780.1K (-65.7%) | 0.24% +0.007 pp | 0.00% 0.000 pp | USD26.05 -76.5% | 11 qtrs — |
| 42 | HSBC HOLDINGS PLC | 66.1K +42.1K (+175.7%) | 402.1K -38.0K (-8.6%) | 0.24% +0.155 pp | 0.00% +0.000 pp | USD11.10 -44.8% | 9 qtrs — |
| 43 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 61.4K -2.0K (-3.2%) | 376.1K -792.1K (-67.8%) | 0.23% -0.008 pp | 0.00% 0.000 pp | USD25.10 -75.6% | 11 qtrs — |
| 44 | NUVEEN, LLC | 52.2K +— (+0.0%) | 320.1K -642.3K (-66.7%) | 0.19% 0.000 pp | 0.00% 0.000 pp | USD10.59 -42.1% | 4 qtrs — |
| 45 | QUANTINNO CAPITAL MANAGEMENT LP | 52.1K +52.1K (+100.0%) | 319.5K +319.5K (+100.0%) | 0.19% +0.192 pp | 0.00% +0.001 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 46 | BARCLAYS PLC | 50.6K -16.8K (-25.0%) | 310.1K -1.3M (-80.2%) | 0.19% -0.062 pp | 0.00% 0.000 pp | USD16.88 -63.7% | 26 qtrs — |
| 47 | KOVACK ADVISORS, INC. | 46.0K +46.0K (+100.0%) | 282.1K +282.1K (+100.0%) | 0.17% +0.169 pp | 0.01% +0.013 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 48 | RUSSELL INVESTMENTS GROUP, LTD. | 44.4K +22.8K (+105.3%) | 272.3K -126.6K (-31.7%) | 0.16% +0.084 pp | 0.00% 0.000 pp | USD8.89 -31.0% | 12 qtrs — |
| 49 | JAIN GLOBAL LLC | 44.1K +44.1K (+100.0%) | 270.2K +270.2K (+100.0%) | 0.16% +0.162 pp | 0.00% +0.001 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 50 | AQR CAPITAL MANAGEMENT LLC | 43.4K +43.4K (+100.0%) | 266.1K +266.1K (+100.0%) | 0.16% +0.160 pp | 0.00% +0.000 pp | USD6.13 +0.0% | 11 qtrs — |
| 51 | WELLS FARGO & COMPANY/MN | 41.3K +8.1K (+24.3%) | 253.3K -359.2K (-58.6%) | 0.15% +0.030 pp | 0.00% 0.000 pp | USD20.78 -70.5% | 27 qtrs — |
| 52 | PANAGORA ASSET MANAGEMENT INC | 34.8K +34.8K (+100.0%) | 213.1K +213.1K (+100.0%) | 0.13% +0.128 pp | 0.00% +0.001 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 53 | SQUAREPOINT OPS LLC | 34.3K +34.3K (+100.0%) | 210.2K +210.2K (+100.0%) | 0.13% +0.126 pp | 0.00% +0.000 pp | USD6.13 +0.0% | 10 qtrs — |
| 54 | BANK OF AMERICA CORP /DE/ | 34.1K -586.0K (-94.5%) | 209.0K -11.2M (-98.2%) | 0.13% -2.160 pp | 0.00% -0.001 pp | USD15.56 -60.6% | 24 qtrs — |
| 55 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 33.2K +3.2K (+10.8%) | 203.3K -349.0K (-63.2%) | 0.12% +0.012 pp | 0.00% -0.001 pp | USD16.85 -63.6% | 7 qtrs — |
| 56 | CANADA PENSION PLAN INVESTMENT BOARD | 30.9K +30.9K (+100.0%) | 189.4K +189.4K (+100.0%) | 0.11% +0.114 pp | 0.00% +0.000 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 57 | RHUMBLINE ADVISERS | 30.7K -9.1K (-22.8%) | 188.0K -544.4K (-74.3%) | 0.11% -0.034 pp | 0.00% 0.000 pp | USD32.72 -81.3% | 23 qtrs — |
| 58 | FORMIDABLE ASSET MANAGEMENT, LLC | 10.1K -200.0 (-1.9%) | 186.1K +52.1K (+38.9%) | 0.04% -0.001 pp | 0.03% +0.006 pp | USD34.26 -82.1% | 20 qtrs — |
| 59 | AXQ CAPITAL, LP | 28.7K +28.7K (+100.0%) | 175.7K +175.7K (+100.0%) | 0.11% +0.105 pp | 0.04% +0.040 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 60 | GREEN ALPHA ADVISORS, LLC | 28.3K +6.8K (+31.9%) | 173.4K -221.8K (-56.1%) | 0.10% +0.025 pp | 0.16% -0.223 pp | USD9.51 -35.5% | 4 qtrs — |
| 61 | MGO ONE SEVEN LLC | 28.1K -6.3K (-18.3%) | 172.4K -462.1K (-72.8%) | 0.10% -0.024 pp | 0.00% -0.011 pp | USD22.15 -72.3% | 26 qtrs — |
| 62 | — | 28.1K +28.1K (+100.0%) | 172.1K +172.1K (+100.0%) | 0.10% +0.103 pp | 0.09% +0.092 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 63 | ALLIANCEBERNSTEIN L.P. | 27.7K -3.4K (-10.9%) | 169.9K -403.6K (-70.4%) | 0.10% -0.013 pp | 0.00% 0.000 pp | USD27.89 -78.0% | 23 qtrs — |
| 64 | ARISTIDES CAPITAL LLC | 26.3K +26.3K (+100.0%) | 161.1K +161.1K (+100.0%) | 0.10% +0.097 pp | 0.03% +0.029 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 65 | PRICE T ROWE ASSOCIATES INC /MD/ | 26.1K -1.8K (-6.6%) | 161.0K -355.0K (-68.8%) | 0.10% -0.007 pp | 0.00% +0.000 pp | USD29.36 -79.1% | 23 qtrs — |
| 66 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 24.7K -3.4K (-12.2%) | 151.3K -366.5K (-70.8%) | 0.09% -0.013 pp | 0.00% -0.001 pp | USD18.43 -66.7% | 2 qtrs — |
| 67 | 683 CAPITAL MANAGEMENT, LLC | 24.0K +24.0K (+100.0%) | 147.1K +147.1K (+100.0%) | 0.09% +0.088 pp | 0.01% +0.006 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 68 | QUEST PARTNERS LLC | 23.7K +11.4K (+91.9%) | 145.4K -82.4K (-36.2%) | 0.09% +0.042 pp | 0.01% -0.007 pp | USD9.80 -37.4% | 9 qtrs — |
| 69 | ALPS ADVISORS INC | 23.3K +10.2K (+78.0%) | 143.0K -98.5K (-40.8%) | 0.09% +0.038 pp | 0.00% -0.001 pp | USD18.00 -65.9% | 11 qtrs — |
| 70 | FREESTONE CAPITAL HOLDINGS, LLC | 18.7K +— (+0.0%) | 114.4K -229.5K (-66.7%) | 0.07% 0.000 pp | 0.00% -0.007 pp | USD23.66 -74.1% | 7 qtrs — |
| 71 | DEUTSCHE BANK AG\ | 18.4K +946.0 (+5.4%) | 112.6K -208.6K (-64.9%) | 0.07% +0.003 pp | 0.00% 0.000 pp | USD19.78 -69.0% | 25 qtrs — |
| 72 | COMMONWEALTH EQUITY SERVICES, LLC | 18.2K -3.2K (-14.9%) | 111.6K -282.4K (-71.7%) | 0.07% -0.012 pp | 0.00% 0.000 pp | USD26.89 -77.2% | 8 qtrs — |
| 73 | BYRNE ASSET MANAGEMENT LLC | 18.1K +17.7K (+4,412.5%) | 110.6K +103.3K (+1,400.9%) | 0.07% +0.065 pp | 0.06% +0.057 pp | USD6.42 -4.5% | 17 qtrs — |
| 74 | DIVERSIFY ADVISORY SERVICES, LLC | 15.0K +— (+0.0%) | 109.4K -30.2K (-21.6%) | 0.06% 0.000 pp | 0.00% -0.001 pp | USD12.81 -52.1% | 4 qtrs — |
| 75 | TEXAS YALE CAPITAL CORP. | 16.0K +— (+0.0%) | 98.1K -196.8K (-66.7%) | 0.06% 0.000 pp | 0.00% -0.006 pp | USD23.66 -74.1% | 7 qtrs — |
| 76 | TOCQUEVILLE ASSET MANAGEMENT L.P. | 13.6K -12.9K (-48.7%) | 83.4K -405.0K (-82.9%) | 0.05% -0.048 pp | 0.00% -0.006 pp | USD20.05 -69.4% | 12 qtrs — |
| 77 | WALLEYE TRADING LLC | 12.4K +600.0 (+5.1%) | 76.0K -141.5K (-65.0%) | 0.05% +0.002 pp | 0.00% 0.000 pp | USD13.03 -53.0% | 3 qtrs — |
| 78 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 12.0K +4.7K (+65.1%) | 73.0K -63.0K (-46.3%) | 0.04% +0.017 pp | 0.00% 0.000 pp | USD18.04 -66.0% | 23 qtrs — |
| 79 | INTECH INVESTMENT MANAGEMENT LLC | 11.4K +11.4K (+100.0%) | 69.8K +69.8K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.001 pp | USD6.13 +0.0% | 4 qtrs — |
| 80 | WALLEYE CAPITAL LLC | 11.2K -6.2K (-35.6%) | 68.7K -252.0K (-78.6%) | 0.04% -0.023 pp | 0.00% -0.001 pp | USD13.38 -54.2% | 8 qtrs — |
| 81 | MERCER GLOBAL ADVISORS INC /ADV | 10.5K +10.5K (+100.0%) | 64.4K +64.4K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 82 | METLIFE INVESTMENT MANAGEMENT, LLC | 9.4K -6.9K (-42.6%) | 57.4K -243.0K (-80.9%) | 0.03% -0.026 pp | 0.00% -0.001 pp | USD33.20 -81.5% | 23 qtrs — |
| 83 | NEW YORK STATE COMMON RETIREMENT FUND | 8.5K +— (+0.0%) | 52.1K -104.5K (-66.7%) | 0.03% 0.000 pp | 0.00% 0.000 pp | USD45.12 -86.4% | 23 qtrs — |
| 84 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 7.7K +— (+0.0%) | 46.9K -94.1K (-66.7%) | 0.03% 0.000 pp | 0.00% 0.000 pp | USD13.01 -52.9% | 3 qtrs — |
| 85 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 7.0K +— (+0.0%) | 42.6K -85.6K (-66.7%) | 0.03% 0.000 pp | 0.00% -0.001 pp | USD17.46 -64.9% | 5 qtrs — |
| 86 | CITIGROUP INC | 5.7K +3.0K (+109.1%) | 35.1K -15.4K (-30.5%) | 0.02% +0.011 pp | 0.00% +0.000 pp | USD13.05 -53.0% | 27 qtrs — |
| 87 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 4.6K -3.1K (-40.3%) | 28.4K -114.6K (-80.2%) | 0.02% -0.012 pp | 0.00% -0.010 pp | USD24.28 -74.8% | 14 qtrs — |
| 88 | LOS ANGELES CAPITAL MANAGEMENT LLC | 2.4K +2.4K (+100.0%) | 22.8K +22.8K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD6.13 +0.0% | 1 qtrs NEW |
| 89 | FMR LLC | 3.2K -130.6K (-97.6%) | 19.8K -2.4M (-99.2%) | 0.01% -0.482 pp | 0.00% 0.000 pp | USD32.20 -81.0% | 26 qtrs — |
| 90 | LEGAL & GENERAL GROUP PLC | 2.5K +— (+0.0%) | 15.3K -30.8K (-66.7%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD32.01 -80.8% | 23 qtrs — |
| 91 | AMERITAS INVESTMENT PARTNERS, INC. | 2.3K +— (+0.0%) | 14.2K -28.5K (-66.7%) | 0.01% +0.000 pp | 0.00% -0.001 pp | USD39.60 -84.5% | 23 qtrs — |
| 92 | SIGNATUREFD, LLC | 2.2K +— (+0.0%) | 13.4K -26.9K (-66.7%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD18.43 -66.7% | 19 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 60 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF ARKG | 1.14% | 14.85M | 0.75% |
| 2 | WisdomTree BioRevolution UCITS ETF - USD Acc WDNA.L | 0.59% | 131.0K | 0.45% |
| 3 | AXS Green Alpha ETF NXTE | 0.22% | 126.5K | 1.00% |
| 4 | ALPS Medical Breakthroughs ETF SBIO | 0.10% | 216.3K | 0.50% |
| 5 | iShares Micro-Cap ETF IWC | 0.04% | 628.4K | 0.60% |
| 6 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.02% | 619.4K | 0.34% |
| 7 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.02% | 226.4K | 0.20% |
| 8 | iShares Biotechnology ETF IBB | 0.01% | 1.30M | 0.44% |
| 9 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.01% | 63.1K | 0.40% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.01% | 10.0K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
293.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+293,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | MULROY DENNIS | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 8.63 | 863.0K | 100,000 | D | ↗ |
| 2025-12-17 | Roberts Joseph | Officer | A-Award | A | Employee Stock Option (right to buy) | 10,000 | 6.52 | 65.2K | 10,000 | D | ↗ |
| 2025-12-17 | Payne Joseph E | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 6.52 | 1.14M | 175,000 | D | ↗ |
| 2025-12-17 | Kurata Lance | Officer | A-Award | A | Employee Stock Option (right to buy) | 54,000 | 6.52 | 352.1K | 54,000 | D | ↗ |
| 2025-12-17 | Chivukula Pad | Officer | A-Award | A | Employee Stock Option (right to buy) | 54,000 | 6.52 | 352.1K | 54,000 | D | ↗ |
| 2025-12-12 | Roberts Joseph | Officer | — | — | Stock Option (Right to Buy) | 9,000 | 16.24 | 146.2K | 0 | D | ↗ |
| 2025-08-15 | SASSINE ANDY | Director / Officer | P-Purchase | A | Common Stock | 1,238 | 16.56 | 20.5K | 221,764 | D | ↗ |
| 2025-06-09 | Slaoui Moncef | Director | A-Award | A | Stock option (right to buy) | 15,000 | 12.54 | 188.1K | 15,000 | D | ↗ |
| 2025-06-09 | Marquet Magda | Director | A-Award | A | Stock option (right to buy) | 15,000 | 12.54 | 188.1K | 15,000 | D | ↗ |
| 2025-06-09 | Markels John | Director | A-Award | A | Stock option (right to buy) | 15,000 | 12.54 | 188.1K | 15,000 | D | ↗ |
| 2025-06-09 | Marantz Jing L. | Director | A-Award | A | Stock option (right to buy) | 15,000 | 12.54 | 188.1K | 15,000 | D | ↗ |
| 2025-06-09 | HOLMES EDWARD W | Director | A-Award | A | Stock option (right to buy) | 15,000 | 12.54 | 188.1K | 15,000 | D | ↗ |
| 2025-06-09 | FARRELL PETER C | Director | A-Award | A | Stock option (right to buy) | 15,000 | 12.54 | 188.1K | 15,000 | D | ↗ |
| 2025-06-09 | BARLOW JAMES F | Director | A-Award | A | Stock option (right to buy) | 15,000 | 12.54 | 188.1K | 15,000 | D | ↗ |
| 2024-12-16 | SASSINE ANDY | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 60,000 | 16.24 | 974.4K | 60,000 | D | ↗ |
| 2024-12-16 | Payne Joseph E | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 196,000 | 16.24 | 3.18M | 196,000 | D | ↗ |
| 2024-12-16 | Kurata Lance | Officer | A-Award | A | Employee Stock Option (right to buy) | 60,000 | 16.24 | 974.4K | 60,000 | D | ↗ |
| 2024-12-16 | Chivukula Pad | Officer | A-Award | A | Employee Stock Option (right to buy) | 60,000 | 16.24 | 974.4K | 60,000 | D | ↗ |
| 2024-10-15 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 12,000 | 20.76 | 249.1K | 435,334 | D | ↗ |
| 2024-06-19 | Slaoui Moncef | Director | A-Award | A | Stock option (right to buy) | 14,794 | 25.96 | 384.1K | 14,794 | — | ↗ |
| 2024-06-14 | Marquet Magda | Director | M-Exempt | D | Deferred Stock Units | 3,131 | 0.00 | — | 0 | — | ↗ |
| 2024-06-14 | Markels John | Director | M-Exempt | D | Deferred Stock Units | 3,131 | 0.00 | — | 0 | — | ↗ |
| 2024-06-14 | Marantz Jing L. | Director | M-Exempt | D | Deferred Stock Units | 3,131 | 0.00 | — | 0 | — | ↗ |
| 2024-06-14 | HOLMES EDWARD W | Director | M-Exempt | D | Deferred Stock Units | 3,131 | 0.00 | — | 0 | — | ↗ |
| 2024-06-14 | FARRELL PETER C | Director | M-Exempt | D | Deferred Stock Units | 3,131 | 0.00 | — | 0 | — | ↗ |
| 2024-06-14 | BARLOW JAMES F | Director | M-Exempt | D | Deferred Stock Units | 3,131 | 0.00 | — | 0 | — | ↗ |
| 2024-06-12 | SASSINE ANDY | Director / Officer | S-Sale | D | Common Stock | 50,000 | 32.03 | 1.60M | 220,526 | — | ↗ |
| 2024-06-05 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 114 | 45.00 | 5.1K | 447,334 | — | ↗ |
| 2024-06-03 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 26,000 | 40.01 | 1.04M | 447,448 | — | ↗ |
| 2024-03-25 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 17,435 | 35.02 | 610.6K | 473,448 | — | ↗ |
| 2024-03-19 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 8,565 | 35.01 | 299.8K | 490,883 | — | ↗ |
| 2023-12-15 | SASSINE ANDY | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 28.88 | 2.17M | 75,000 | — | ↗ |
| 2023-12-15 | Payne Joseph E | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 28.88 | 5.78M | 200,000 | — | ↗ |
| 2023-12-15 | Kurata Lance | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 28.88 | 2.17M | 75,000 | — | ↗ |
| 2023-12-15 | Kummerfeld Keith C | Officer | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 28.88 | 866.4K | 30,000 | — | ↗ |
| 2023-12-15 | Chivukula Pad | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 28.88 | 3.61M | 125,000 | — | ↗ |
| 2023-11-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 5,000 | 18.72 | 93.6K | 499,448 | — | ↗ |
| 2023-10-02 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 5,000 | 25.61 | 128.1K | 504,448 | — | ↗ |
| 2023-09-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 5,000 | 31.45 | 157.3K | 509,448 | — | ↗ |
| 2023-08-15 | SASSINE ANDY | Director / Officer | A-Award | A | Common Stock | 1,223 | 17.37 | 21.2K | 270,526 | — | ↗ |
| 2023-08-01 | Marquet Magda | Director | A-Award | A | Stock option (right to buy) | 11,869 | 34.92 | 414.5K | 11,869 | — | ↗ |
| 2023-08-01 | Markels John | Director | A-Award | A | Deferred Stock Units | 3,131 | 0.00 | — | 3,131 | — | ↗ |
| 2023-08-01 | Marantz Jing L. | Director | A-Award | A | Deferred Stock Units | 3,131 | 0.00 | — | 3,131 | — | ↗ |
| 2023-08-01 | HOLMES EDWARD W | Director | A-Award | A | Stock Option (right to buy) | 11,869 | 34.92 | 414.5K | 11,869 | — | ↗ |
| 2023-08-01 | FARRELL PETER C | Director | A-Award | A | Deferred Stock Units | 3,131 | 0.00 | — | 3,131 | — | ↗ |
| 2023-08-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 5,000 | 34.91 | 174.6K | 514,448 | — | ↗ |
| 2023-08-01 | BARLOW JAMES F | Director | A-Award | A | Deferred Stock Units | 3,131 | 0.00 | — | 3,131 | — | ↗ |
| 2023-07-14 | Kummerfeld Keith C | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,437 | 4.99 | 7.2K | 7,126 | — | ↗ |
| 2023-07-14 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 25,000 | 35.01 | 875.3K | 519,448 | — | ↗ |
| 2023-07-03 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 5,000 | 28.75 | 143.8K | 544,448 | — | ↗ |
| 2023-06-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 5,000 | 27.16 | 135.8K | 549,448 | — | ↗ |
| 2023-05-11 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 7,925 | 30.24 | 239.7K | 554,448 | — | ↗ |
| 2023-05-10 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 17,075 | 30.00 | 512.3K | 562,373 | — | ↗ |
| 2023-05-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 5,000 | 25.93 | 129.7K | 579,448 | — | ↗ |
| 2023-04-18 | Kummerfeld Keith C | Officer | M-Exempt | A | Common Stock | 1,031 | 14.12 | 14.6K | 1,981 | — | ↗ |
| 2023-04-17 | Kummerfeld Keith C | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 1,031 | 14.12 | 14.6K | 8,969 | — | ↗ |
| 2023-04-03 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 5,000 | 25.38 | 126.9K | 584,448 | — | ↗ |
| 2023-03-06 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 5,000 | 16.07 | 80.4K | 589,448 | — | ↗ |
| 2022-12-15 | Marquet Magda | Director | P-Purchase | A | Common Stock | 2,222 | 18.00 | 40.0K | 24,942 | — | ↗ |
| 2022-12-09 | SASSINE ANDY | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-12-09 | Payne Joseph E | Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-12-09 | Kurata Lance | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-12-09 | Kummerfeld Keith C | Officer | A-Award | A | Employee Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-12-09 | Chivukula Pad | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-12-08 | Markels John | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-11-23 | Payne Joseph E | Officer | P-Purchase | A | Common Stock | 5,000 | 16.51 | 82.6K | 1,480,097 | — | ↗ |
| 2022-08-15 | SASSINE ANDY | Officer | A-Award | A | Common Stock | 1,068 | 18.42 | 19.7K | 269,303 | — | ↗ |
| 2022-06-23 | Marquet Magda | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-23 | Marantz Jing L. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 16.02 | 240.3K | 15,000 | — | ↗ |
| 2022-06-23 | HOLMES EDWARD W | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-23 | FARRELL PETER C | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 16.02 | 240.3K | 15,000 | — | ↗ |
| 2022-06-23 | BARLOW JAMES F | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 16.02 | 240.3K | 15,000 | — | ↗ |
| 2022-06-21 | SASSINE ANDY | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 85,000 | 34.57 | 2.94M | 85,000 | — | ↗ |
| 2022-06-21 | Payne Joseph E | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2022-06-21 | Kurata Lance | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-06-21 | Kummerfeld Keith C | Officer | A-Award | A | Employee Stock Option (right to buy) | 33,000 | 0.00 | — | 33,000 | — | ↗ |
| 2022-06-21 | Chivukula Pad | Officer | A-Award | A | Employee Stock Option (right to buy) | 85,000 | 34.57 | 2.94M | 85,000 | — | ↗ |
| 2022-01-04 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 8,100 | 40.00 | 324.0K | 594,448 | — | ↗ |
| 2021-12-16 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 3,633 | 40.00 | 145.3K | 602,548 | — | ↗ |
| 2021-12-08 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 6,367 | 40.00 | 254.7K | 606,181 | — | ↗ |
| 2021-12-07 | Marantz Jing L. | Director | A-Award | A | Stock option (right to buy) | 20,000 | 38.54 | 770.8K | 20,000 | — | ↗ |
| 2021-11-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 44.41 | 444.1K | 612,548 | — | ↗ |
| 2021-10-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 44.36 | 443.6K | 622,548 | — | ↗ |
| 2021-09-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 55.86 | 558.6K | 632,548 | — | ↗ |
| 2021-08-11 | Ultragenyx Pharmaceutical Inc. | Director | S-Sale | D | Common Stock | 75,000 | 45.83 | 3.44M | 1,400,000 | — | ↗ |
| 2021-08-10 | Ultragenyx Pharmaceutical Inc. | Director | S-Sale | D | Common Stock | 725,000 | 55.44 | 40.19M | 1,475,000 | — | ↗ |
| 2021-08-03 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 40.07 | 400.7K | 642,548 | — | ↗ |
| 2021-06-18 | Parschauer Karah Herdman | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 35.09 | 526.4K | 15,000 | — | ↗ |
| 2021-06-18 | Marquet Magda | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 35.09 | 526.4K | 15,000 | — | ↗ |
| 2021-06-18 | HOLMES EDWARD W | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 35.09 | 526.4K | 15,000 | — | ↗ |
| 2021-06-18 | FARRELL PETER C | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 35.09 | 526.4K | 15,000 | — | ↗ |
| 2021-06-18 | BARLOW JAMES F | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 35.09 | 526.4K | 15,000 | — | ↗ |
| 2021-04-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 42.95 | 429.5K | 652,548 | — | ↗ |
| 2021-03-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 54.23 | 542.3K | 662,548 | — | ↗ |
| 2021-02-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 75.31 | 753.1K | 672,548 | — | ↗ |
| 2021-01-04 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 46.40 | 464.0K | 682,548 | — | ↗ |
| 2020-12-18 | SASSINE ANDY | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 99.29 | 9.93M | 100,000 | — | ↗ |
| 2020-12-18 | Payne Joseph E | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 175,000 | 99.29 | 17.38M | 175,000 | — | ↗ |
| 2020-12-18 | Kurata Lance | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 99.29 | 2.48M | 25,000 | — | ↗ |
| 2020-12-18 | Kummerfeld Keith C | Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 99.29 | 4.47M | 45,000 | — | ↗ |
| 2020-12-18 | Hughes Steven George | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 99.29 | 4.96M | 50,000 | — | ↗ |
| 2020-12-18 | Chivukula Pad | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 99.29 | 9.93M | 100,000 | — | ↗ |
| 2020-12-09 | Ultragenyx Pharmaceutical Inc. | Director / 10% Owner | S-Sale | D | Common Stock | 357,745 | 94.97 | 33.98M | 2,200,000 | — | ↗ |
| 2020-12-08 | Ultragenyx Pharmaceutical Inc. | Director / 10% Owner | S-Sale | D | Common Stock | 442,255 | 105.54 | 46.68M | 2,557,745 | — | ↗ |
| 2020-12-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 96.19 | 961.9K | 692,548 | — | ↗ |
| 2020-11-02 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 55.28 | 552.8K | 702,548 | — | ↗ |
| 2020-10-01 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 42.83 | 428.3K | 712,548 | — | ↗ |
| 2020-09-03 | Chivukula Pad | Officer | S-Sale | D | Common Stock | 10,000 | 45.16 | 451.6K | 722,548 | — | ↗ |
| 2020-08-10 | Kurata Lance | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 58.91 | 5.30M | 90,000 | — | ↗ |
| 2020-06-22 | Parschauer Karah Herdman | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 40.70 | 610.5K | 15,000 | — | ↗ |
| 2020-06-22 | Marquet Magda | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 40.70 | 610.5K | 15,000 | — | ↗ |
| 2020-06-22 | HOLMES EDWARD W | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 40.70 | 610.5K | 15,000 | — | ↗ |
| 2020-06-22 | FARRELL PETER C | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 40.70 | 610.5K | 15,000 | — | ↗ |
| 2020-06-22 | BARLOW JAMES F | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 40.70 | 610.5K | 15,000 | — | ↗ |
| 2020-06-12 | Kummerfeld Keith C | Officer | P-Purchase | A | Common Stock | 450 | 33.33 | 15.0K | 950 | — | ↗ |
| 2020-06-10 | SASSINE ANDY | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 29.74 | 148.7K | 273,245 | — | ↗ |
| 2020-06-10 | Payne Joseph E | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 31.69 | 31.7K | 1,475,097 | — | ↗ |
| 2020-05-20 | Ultragenyx Pharmaceutical Inc. | Director / 10% Owner | M-Exempt | A | Common Stock | 600,000 | 16.00 | 9.60M | 3,000,000 | — | ↗ |
| 2020-02-18 | SASSINE ANDY | Director / Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 14.12 | 1.13M | 80,000 | — | ↗ |
| 2020-02-18 | Payne Joseph E | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 100,000 | 14.12 | 1.41M | 100,000 | — | ↗ |
| 2020-02-18 | Kummerfeld Keith C | Officer | A-Award | A | Stock Option (right to buy) | 10,000 | 14.12 | 141.2K | 10,000 | — | ↗ |
| 2020-02-18 | Hughes Steven George | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 14.12 | 1.06M | 75,000 | — | ↗ |
| 2020-02-18 | Chivukula Pad | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 14.12 | 847.2K | 60,000 | — | ↗ |
| 2019-12-05 | SASSINE ANDY | Director / Officer | P-Purchase | A | Common Stock | 5,649 | 9.73 | 55.0K | 268,245 | — | ↗ |
| 2019-12-03 | SASSINE ANDY | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 10.00 | 100.0K | 257,596 | — | ↗ |
| 2019-10-25 | Parschauer Karah Herdman | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 10.23 | 153.5K | 15,000 | — | ↗ |
| 2019-10-25 | Marquet Magda | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 10.23 | 153.5K | 15,000 | — | ↗ |
| 2019-10-25 | HOLMES EDWARD W | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 10.23 | 153.5K | 15,000 | — | ↗ |
| 2019-10-25 | FARRELL PETER C | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 10.23 | 153.5K | 15,000 | — | ↗ |
| 2019-10-25 | BARLOW JAMES F | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 10.23 | 153.5K | 15,000 | — | ↗ |
| 2019-09-17 | HOLMES EDWARD W | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-09-13 | Marquet Magda | Director | P-Purchase | A | Common Stock | 2,300 | 10.58 | 24.3K | 22,720 | — | ↗ |
| 2019-09-12 | Kummerfeld Keith C | Officer | P-Purchase | A | Common Stock | 500 | 10.69 | 5.3K | 500 | — | ↗ |
| 2019-08-29 | Payne Joseph E | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 11.22 | 56.1K | 1,474,097 | — | ↗ |
| 2019-08-23 | SASSINE ANDY | Officer | P-Purchase | A | Common Stock | 10,000 | 10.90 | 109.0K | 247,596 | — | ↗ |
| 2019-08-20 | FARRELL PETER C | Director | P-Purchase | A | Common Stock | 4,432 | 10.85 | 48.1K | 42,955 | — | ↗ |
| 2019-08-19 | FARRELL PETER C | Director | P-Purchase | A | Common Stock | 4,681 | 11.02 | 51.6K | 38,523 | — | ↗ |
| 2019-06-19 | Ultragenyx Pharmaceutical Inc. | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,400,000 | — | ↗ |
| 2019-06-19 | Parschauer Karah Herdman | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-07 | Chivukula Pad | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 38,333 | 4.99 | 191.3K | 38,333 | — | ↗ |
| 2019-01-01 | SASSINE ANDY | Director / Officer | — | D | Ordinary Shares | 0 | 0.00 | — | 237,596 | — | ↗ |
| 2019-01-01 | Marquet Magda | Director | — | D | Ordinary Shares | 0 | 0.00 | — | 20,500 | — | ↗ |
| 2019-01-01 | FARRELL PETER C | Director | — | D | Ordinary Shares | 0 | 0.00 | — | 86,452 | — | ↗ |
| 2019-01-01 | Chivukula Pad | Officer | — | D | Ordinary Shares | 0 | 0.00 | — | 732,548 | — | ↗ |
| 2019-01-01 | BARLOW JAMES F | Director | — | D | Ordinary Shares | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2018-08-24 | Marquet Magda | Director | — | D | STOCK OPTION (right to purchase) | 2,500 | 8.00 | 20.0K | 0 | — | ↗ |
| 2018-08-24 | FARRELL PETER C | Director | — | D | STOCK OPTION (right to purchase) | 2,500 | 8.00 | 20.0K | 0 | — | ↗ |
| 2018-08-24 | BARLOW JAMES F | Director | — | D | STOCK OPTION (right to purchase) | 2,500 | 8.00 | 20.0K | 0 | — | ↗ |
| 2013-01-22 | Stanley William G | Director | D-Return | D | Stock Option | 3,000 | 10.00 | 30.0K | 0 | — | ↗ |
| 2013-01-22 | SCHORSCH NICHOLAS S | Director | D-Return | D | Common Stock, par value $0.01 per share | 7,540 | 0.00 | — | 0 | — | ↗ |
| 2013-01-22 | MICHELSON LESLIE D | Director | D-Return | D | Stock Option | 3,000 | 10.00 | 30.0K | 0 | — | ↗ |
| 2013-01-22 | KAHANE WILLIAM M | Director / Officer | D-Return | D | Common Stock, par value $0.01 per share | 7,540 | 0.00 | — | 0 | — | ↗ |
| 2013-01-22 | Jones Brian D | Officer | D-Return | D | Common Stock, par value $0.01 per share | 24,952 | 0.00 | — | 0 | — | ↗ |
| 2013-01-22 | Burns Robert | Director | D-Return | D | Common Stock, par value $0.01 per share | 96,085 | 0.00 | — | 0 | — | ↗ |
| 2012-06-18 | Stanley William G | Director | A-Award | A | Common Stock, par value $0.01 per share | 4,771 | 0.00 | — | 44,667 | — | ↗ |
| 2012-06-18 | MICHELSON LESLIE D | Director | A-Award | A | Common Stock, par value $0.01 per share | 4,771 | 0.00 | — | 30,401 | — | ↗ |
| 2012-06-18 | Jones Brian D | Officer | A-Award | A | Common Stock | 13,502 | 0.00 | — | 24,952 | — | ↗ |
| 2012-06-18 | Burns Robert | Director | A-Award | A | Common Stock, par value $0.01 per share | 4,771 | 0.00 | — | 96,085 | — | ↗ |
| 2012-04-18 | Jones Brian D | Officer | P-Purchase | A | Common Stock, par value $0.01 per share | 1,000 | 11.00 | 11.0K | 11,450 | — | ↗ |
| 2012-04-17 | SCHORSCH NICHOLAS S | Director | P-Purchase | A | Common Stock, par value $0.01 per share | 10,000 | 11.10 | 111.0K | 993,240 | — | ↗ |
| 2012-04-17 | KAHANE WILLIAM M | Director / Officer | P-Purchase | A | Common Stock, par value $0.01 per share | 10,000 | 11.10 | 111.0K | 261,451 | — | ↗ |
| 2012-03-01 | Jones Brian D | Officer | — | D | Common Stock, par value $0.01 | 0 | 0.00 | — | 10,450 | — | ↗ |
| 2012-03-01 | Budko Peter M | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-03-01 | BLOCK BRIAN S | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-01-09 | KAHANE WILLIAM M | Director / Officer | G-Gift | D | Common Stock, par value $0.01 per share | 5,000 | 0.00 | — | 251,451 | — | ↗ |
| 2011-10-01 | Stanley William G | Director | A-Award | A | Common Stock, par value $0.01 per share | 13,818 | 9.00 | 124.4K | 26,451 | — | ↗ |
| 2011-10-01 | Burns Robert | Director | A-Award | A | Common Stock, par value $0.01 per share | 9,818 | 9.00 | 88.4K | 66,895 | — | ↗ |
| 2011-05-24 | Stanley William G | Director | A-Award | A | Common Stock, par value $0.01 per share | 3,000 | 0.00 | — | 12,633 | — | ↗ |
| 2011-05-24 | MICHELSON LESLIE D | Director | A-Award | A | Common Stock, par value $0.01 per share | 3,000 | 0.00 | — | 12,550 | — | ↗ |
| 2011-05-24 | Burns Robert | Director | A-Award | A | Common Stock, par value $0.01 per share | 3,000 | 0.00 | — | 57,077 | — | ↗ |
| 2010-05-17 | Burns Robert | Director | A-Award | A | Stock Option | 3,000 | 10.00 | 30.0K | 9,000 | — | ↗ |
| 2009-05-22 | Stanley William G | Director | A-Award | A | Stock Option | 3,000 | 10.00 | 30.0K | 6,000 | — | ↗ |
| 2009-05-22 | MICHELSON LESLIE D | Director | A-Award | A | Stock Option | 3,000 | 10.00 | 30.0K | 6,000 | — | ↗ |
| 2009-05-22 | Burns Robert | Director | A-Award | A | Stock Option | 3,000 | 10.00 | 30.0K | 6,000 | — | ↗ |
| 2008-01-22 | Stanley William G | Director | A-Award | A | Stock Option | 3,000 | 10.00 | 30.0K | 3,000 | — | ↗ |
| 2008-01-22 | MICHELSON LESLIE D | Director | A-Award | A | Stock Option | 3,000 | 10.00 | 30.0K | 3,000 | — | ↗ |
| 2008-01-22 | Burns Robert | Director | A-Award | A | Stock Option | 3,000 | 10.00 | 30.0K | 3,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-430.8K
Shares Outstanding
28.42M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Joseph E. Payne President and Chief Executive Officer, Director | 750.0K | — | — | 941.0K | — | — | 1.69M | 55.65% | ↗ |
| 2 | 2025 | Andy Sassine Former Chief Financial Officer | 572.0K | — | — | 37.5K | — | 572.0K | 1.18M | 3.17% | ↗ |
| 3 | 2025 | Dr. Padmanabh Chivukula Chief Scientific Officer, Chief Operating Officer | 572.0K | — | — | 290.0K | — | — | 862.0K | 33.64% | ↗ |
| 4 | 2025 | Lance Kurata Chief Legal Officer | 540.0K | — | — | 290.0K | — | — | 830.0K | 34.94% | ↗ |
| 5 | 2025 | Joe Roberts Interim Principal Financial Officer and Accounting Officer; Controller | 219.6K | — | — | 54.0K | — | — | 273.6K | 19.74% | ↗ |
| 6 | 2024 | Joseph E. Payne President and Chief Executive Officer, Director | 695.0K | 367.0K | — | 2.64M | — | — | 3.70M | 71.27% | ↗ |
| 7 | 2024 | Joseph E. Payne President and Chief Executive Officer, Director | 695.0K | 367.0K | — | 2.64M | — | — | 3.70M | 71.27% | ↗ |
| 8 | 2024 | Andy Sassine Chief Financial Officer, Director | 550.0K | 261.0K | — | 807.0K | — | — | 1.62M | 49.88% | ↗ |
| 9 | 2024 | Andy Sassine Former Chief Financial Officer | 550.0K | 261.0K | — | 807.0K | — | — | 1.62M | 49.88% | ↗ |
| 10 | 2024 | Dr. Padmanabh Chivukula Chief Scientific Officer, Chief Operating Officer | 550.0K | 228.0K | — | 807.0K | — | — | 1.59M | 50.91% | ↗ |
| 11 | 2024 | Dr. Padmanabh Chivukula Chief Scientific Officer, Chief Operating Officer | 550.0K | 228.0K | — | 807.0K | — | — | 1.59M | 50.91% | ↗ |
| 12 | 2024 | Lance Kurata Chief Legal Officer | 500.0K | 180.0K | — | 807.0K | — | — | 1.49M | 54.27% | ↗ |
| 13 | 2024 | Lance Kurata Chief Legal Officer | 500.0K | 180.0K | — | 807.0K | — | — | 1.49M | 54.27% | ↗ |
| 14 | 2024 | Joe Roberts Interim Principal Financial Officer and Accounting Officer; Controller | 211.1K | 38.0K | — | 156.6K | — | — | 405.7K | 38.59% | ↗ |
| 15 | 2023 | Joseph E. Payne President and Chief Executive Officer, Director | 698.0K | 208.5K | — | 3.99M | — | — | 4.89M | 81.47% | ↗ |
| 16 | 2023 | Joseph E. Payne President and Chief Executive Officer, Director | 698.0K | 208.5K | — | 3.99M | — | — | 4.89M | 81.47% | ↗ |
| 17 | 2023 | Dr. Padmanabh Chivukula Chief Scientific Officer, Chief Operating Officer | 550.0K | 137.5K | — | 2.49M | — | — | 3.18M | 78.37% | ↗ |
| 18 | 2023 | Dr. Padmanabh Chivukula Chief Scientific Officer, Chief Operating Officer | 550.0K | 137.5K | — | 2.49M | — | — | 3.18M | 78.37% | ↗ |
| 19 | 2023 | Andy Sassine Former Chief Financial Officer | 550.0K | 137.5K | — | 1.50M | — | — | 2.18M | 68.50% | ↗ |
| 20 | 2023 | Andy Sassine Chief Financial Officer, Director | 550.0K | 137.5K | — | 1.50M | — | — | 2.18M | 68.50% | ↗ |
| 21 | 2023 | Lance Kurata Chief Legal Officer | 500.0K | 100.0K | — | 1.50M | — | — | 2.10M | 71.36% | ↗ |
| 22 | 2023 | Lance Kurata Chief Legal Officer | 500.0K | 100.0K | — | 1.50M | — | — | 2.10M | 71.36% | ↗ |
| 23 | 2023 | Joe Roberts Interim Principal Financial Officer and Accounting Officer; Controller | 182.0K | 16.4K | — | 149.5K | — | — | 347.9K | 42.97% | ↗ |
| 24 | 2022 | Joseph E. Payne President and Chief Executive Officer, Director | 630.0K | 504.0K | — | 4.46M | — | — | 5.59M | 79.73% | ↗ |
| 25 | 2022 | Andy Sassine, Chief Financial Officer, Director | 525.0K | 301.9K | — | 2.32M | — | — | 3.15M | 73.71% | ↗ |
| 26 | 2022 | Andy Sassine Chief Financial Officer, Director | 525.0K | 301.9K | — | 2.32M | — | — | 3.15M | 73.71% | ↗ |
| 27 | 2022 | Dr. Padmanabh Chivukula Chief Scientific Officer, Chief Operating Officer | 525.0K | 262.5K | — | 2.32M | — | — | 3.11M | 74.65% | ↗ |
| 28 | 2022 | Lance Kurata Chief Legal Officer | 435.0K | 304.5K | — | 442.5K | — | — | 1.18M | 37.44% | ↗ |
| 29 | 2021 | Joseph E. Payne President and Chief Executive Officer, Director | 600.0K | 360.0K | — | — | — | — | 960.0K | 0.00% | ↗ |
| 30 | 2021 | Andy Sassine, Chief Financial Officer | 500.0K | 250.0K | — | — | — | — | 750.0K | 0.00% | ↗ |
| 31 | 2021 | Dr. Padmanabh Chivukula Chief Scientific Officer, Chief Operating Officer | 500.0K | 250.0K | — | — | — | — | 750.0K | 0.00% | ↗ |
| 32 | 2021 | Andy Sassine, Chief Financial Officer, Director | 500.0K | 250.0K | — | — | — | — | 750.0K | 0.00% | ↗ |
| 33 | 2021 | Dr. Steven Hughes Former Chief Medical Officer | 460.0K | 184.0K | — | — | — | — | 644.0K | 0.00% | ↗ |
| 34 | 2021 | Lance Kurata Chief Legal Officer | 400.0K | 160.0K | — | — | — | — | 560.0K | 0.00% | ↗ |
| 35 | 2020 | Joseph E. Payne President and Chief Executive Officer, Director | 500.0K | 450.0K | — | 11.91M | — | — | 12.86M | 92.61% | ↗ |
| 36 | 2020 | Andy Sassine, Chief Financial Officer | 400.0K | 240.0K | — | 7.01M | — | — | 7.65M | 91.64% | ↗ |
| 37 | 2020 | Dr. Padmanabh Chivukula Chief Scientific Officer, Chief Operating Officer | 400.0K | 240.0K | — | 6.83M | — | — | 7.47M | 91.44% | ↗ |
| 38 | 2020 | Lance Kurata Chief Legal Officer | 156.3K | 67.5K | — | 4.92M | — | — | 5.14M | 95.65% | ↗ |
| 39 | 2020 | Lance Kurata Chief Legal Officer | 156.3K | 67.5K | — | 4.92M | — | — | 5.14M | 95.65% | ↗ |
| 40 | 2020 | Dr. Steven Hughes Chief Medical Officer | 415.0K | 249.0K | — | 4.21M | — | — | 4.88M | 86.38% | ↗ |
| 41 | 2020 | Dr. Steven Hughes Former Chief Medical Officer | 415.0K | 249.0K | — | 4.21M | — | — | 4.88M | 86.38% | ↗ |
| 42 | 2019 | Andy Sassine, Chief Financial Officer | 375.0K | 150.0K | — | 801.9K | — | — | 1.33M | 60.43% | ↗ |
| 43 | 2019 | Joseph E. Payne President and Chief Executive Officer, Director | 450.0K | 243.0K | — | 472.8K | — | — | 1.17M | 40.56% | ↗ |
| 44 | 2019 | Dr. Padmanabh Chivukula Chief Scientific Officer, Chief Operating Officer | 370.0K | 133.2K | — | 133.0K | — | — | 636.2K | 20.90% | ↗ |
| 45 | 2019 | Dr. Steven Hughes Chief Medical Officer | 299.9K | — | — | — | — | — | 299.9K | 0.00% | ↗ |
| 46 | 2018 | Joseph E. Payne President and Chief Executive Officer, Director | 425.0K | 372.5K | — | — | — | 1.25M | 2.69M | 0.00% | ↗ |
| 47 | 2018 | Dr. Padmanabh Chivukula Chief Scientific Officer, Chief Operating Officer | 350.0K | 83.2K | — | — | — | 515.1K | 1.37M | 0.00% | ↗ |
| 48 | 2018 | Dr. Padmanabh Chivukula Chief Scientific Officer and Chief Operating Officer | 350.0K | 83.2K | — | 424.6K | — | 515.1K | 1.37M | 30.93% | ↗ |
| 49 | 2018 | Mark Herbert Interim President | 307.2K | — | — | — | — | 153.6K | 460.8K | 0.00% | ↗ |
| 50 | 2018 | Andy Sassine, Chief Financial Officer | 120.0K | — | — | — | — | — | 246.3K | 0.00% | ↗ |
| 51 | 2018 | Andy Sassine Interim Chief Financial Officer | 120.0K | — | — | 126.3K | — | — | 246.3K | 51.29% | ↗ |
| 52 | 2017 | Joseph E. Payne President and Chief Executive Officer, Director | 384.0K | 40.8K | — | — | — | 24.0K | 448.8K | 0.00% | ↗ |
| 53 | 2017 | Dr. Padmanabh Chivukula Chief Scientific Officer and Chief Operating Officer | 335.0K | 40.8K | — | — | — | 72.00 | 375.9K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joseph E. Payne | Founder, President, Chief Executive Officer & Director | 750.0K | male |
| Padmanabh Chivukula | Founder, Chief Scientific Officer, Chief Operating Officer & Secretary | 572.0K | — |
| Lance Kurata | Chief Legal Officer | 540.0K | male |
| Joseph Roberts | Principal Financial & Accounting Officer and Controller | 219.6K | male |
| Neda Safarzadeh | Vice President and Head of IR/PR & Marketing | — | female |
| Alan H. Cohen FAAAAI FAAP FACAAI FCCP | Chief Medical Officer | — | — |
| Ye Zhang | Chief Regulatory & Quality Assurance Officer | — | — |
| Igor Smolenov | Chief Development Officer | — | — |
| Kevin T. Skol | Chief Business Officer | — | male |
| Natash O. Bowman | Chief Human Resources Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARCT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
